Translational Development Acquisition Corp. (TDAC) Financial Ratios
3 years of historical data (2022–2024) · Financial Services · Shell Companies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.26
—
5yr avg: N/A
ROE
-0.1%
+0% vs avg
5yr avg: -0.1%
30Y Low-0%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TDAC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Translational Development Acquisition Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $183M | — | — | — |
| Enterprise Value | $183M | — | — | — |
| P/E Ratio → | -656.17 | — | — | — |
| P/S Ratio | 172.05 | — | — | — |
| P/B Ratio | 0.26 | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TDAC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
TDAC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Translational Development Acquisition Corp. earns an operating margin of -18.4%, below the Financial Services sector average of 21.6%. A negative ROE of -0.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | — | — |
| Operating Margin | -18.4% | -18.4% | — | — |
| Net Profit Margin | -6.7% | -6.7% | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | -0.1% | -0.1% | — | — |
| ROA | -0.1% | -0.1% | -221.1% | -16.2% |
| ROIC | -0.2% | -0.2% | -949.2% | — |
| ROCE | -0.2% | -0.2% | — | — |
TDAC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $438174 exceeds total debt of $347500, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -0.00 | — | — |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -0.14 | -0.14 | — | — |
Net cash position: cash ($438174) exceeds total debt ($347500)
TDAC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Translational Development Acquisition Corp.'s current ratio of 3.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.12x to 3.09x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 0.00 | 0.12 |
| Quick Ratio | 3.09 | 3.09 | 0.00 | 0.12 |
| Cash Ratio | 2.08 | 2.08 | 0.00 | 0.00 |
| Asset Turnover | — | 0.01 | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
TDAC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Translational Development Acquisition Corp. returns 0.3% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | 0.3% | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — |
| Total Shareholder Yield | 0.3% | — | — | — |
| Shares Outstanding | — | $4M | $4M | $4M |
Peer Comparison
Compare TDAC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TDACYou | $183M | -656.2 | — | — | 69.9% | -18.4% | -0.1% | -0.2% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 HCAI | $16M | 9.7 | 8.8 | 10.4 | 14.0% | 5.5% | 5.5% | 4.2% | 3.8 |
 GS | $288B | 22.8 | 34.8 | — | 41.1% | 14.5% | 12.0% | 1.9% | 29.7 |
 MS | $303B | 23.9 | 25.8 | — | 55.6% | 17.1% | 13.0% | 2.9% | 15.8 |
 JPM | $826B | 15.5 | 13.3 | — | 58.6% | 27.7% | 17.4% | 5.4% | 9.0 |
 EVR | $13B | 23.6 | 15.9 | 11.1 | 99.4% | 20.5% | 27.8% | 18.8% | 1.4 |
 LAZ | $4B | 21.4 | 12.1 | 8.6 | 31.8% | 13.0% | 27.0% | 9.5% | 5.7 |
 PJT | $4B | 22.9 | 9.1 | 7.7 | 32.4% | 21.2% | 18.9% | 20.3% | 1.1 |
 RLAY | $2B | -7.8 | — | — | 76.8% | -1971.6% | -41.1% | -37.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
| Financial Services Median | — | 13.1 | 11.5 | 10.6 | 63.6% | 21.6% | 9.4% | 5.7% | 4.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
See TDAC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TDAC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TDAC vs NUVB
Side-by-side business, growth, and profitability comparison vs Nuvation Bio Inc..
Start ComparisonTDAC — Frequently Asked Questions
Quick answers to the most common questions about buying TDAC stock.
What is Translational Development Acquisition Corp.'s P/E ratio?
Translational Development Acquisition Corp.'s current P/E ratio is -656.2x. This places it at the 50th percentile of its historical range.
What is Translational Development Acquisition Corp.'s ROE?
Translational Development Acquisition Corp.'s return on equity (ROE) is -0.1%. The historical average is -0.1%.
Is TDAC stock overvalued?
Based on historical data, Translational Development Acquisition Corp. is trading at a P/E of -656.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Translational Development Acquisition Corp.'s dividend yield?
Translational Development Acquisition Corp.'s current dividend yield is 0.29%.
What are Translational Development Acquisition Corp.'s profit margins?
Translational Development Acquisition Corp. has 69.9% gross margin and -18.4% operating margin.